Rivastigmine Study in Adolescents With Down Syndrome

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Down Syndrome

In brief

The purpose of this study is to determine if short term use of rivastigmine can improve functional abilities (for example, language, memory, and executive function) in adolescents with Down syndrome.

Key facts

Study ID

NCT01084135

Run by

Duke University

People needed

42

Starts

2009-11-01

Expected to finish

2014-02-01

Last updated by the study team

2015-04-06

Who can join

Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Correct VERBAL responses for 7/9 of the Expressive One Word Picture Vocabulary Test items.
• Subject able to put at least 2-3 words together in conversational speech.
• Subject's speech is understandable to the examiner for the majority of the time.
• Subjects are in good health and medically stable

You may not qualify if…

• Subject uses sign language as a primary means of communication
• Subject has a medical history that contraindicate the use of rivastigmine (For example, patients with active seizure disorders, asthma, celiac disease, heart disease or heart rhythm disorders).

Where it is running

• Kennedy Krieger Institute — Baltimore, Maryland, United States
• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.